Novo Nordisk’s Strategic Acquisition of Catalent: Short-term Challenges but Long-term Growth Potential with a Buy Recommendation
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...
How Trump’s Greenland demands could impact Ozempic costs
President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...
Trump’s plan to impose tariffs in bid to acquire Greenland could raise prices of Ozempic, Legos
President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to ...
24/7 Wall St3d
Novo Nordisk A/S (NVO) Price Prediction and Forecast 2025-2030
With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...
Nasdaq13d
Better Buy: Novo Nordisk vs. AstraZeneca
Novo Nordisk (NYSE: NVO) and AstraZeneca (NASDAQ: AZN) are among the largest companies in the pharmaceutical industry. Both have generally produced strong financial results in 2024, but one wouldn ...